



■ TEL : 022 - 6825 2525  
■ FAX : 022 - 2405 7708  
■ E-Mail : info@naxparlab.com  
■ Visit us at: www.naxparlab.com  
■ CIN No. : L36912MH1982PLC027925

# Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,  
SION-CHUNABHATTI, MUMBAI - 400 022. INDIA

**Date: 14<sup>th</sup> November, 2024**

To,  
Department of Corporate Service (DCS-CRD),  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400001.

**Sub: Outcome of Board Meeting and Intimation of Change of Designation of Directors pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**Ref: Submission of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September 30, 2024, in pursuance of Regulation 33 of Listing Obligation and Disclosure Requirement, 2015.**

**Ref: Parnax Lab Limited, Script Code- 506128**

Dear Sir,

Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) 2015, read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR Regulations) and SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., **Thursday, 14<sup>th</sup> November, 2024**, at its Registered Office, has inter alia, approved and taken note of the following decisions:

1. Considered and Approved the Standalone & Consolidated Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2024, along with Limited Review Report thereon.

A Copy of Standalone & Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30<sup>th</sup> September, 2024, along with Limited Review Report thereon, pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2015, is enclosed herewith as Annexure II.

2. In supersession of the Ordinary Resolution, passed by the Members of the Company through Postal Ballot and Remote E-Voting on 05<sup>th</sup> July, 2024 for Appointment of Mr. Mihir Prakash Shah as the Director and CEO of the Company, now the Nomination and Remuneration Committee (NRC) at its Meeting held prior to this Meeting has approved and recommended the Change in designation of Mr. Mihir Prakash Shah from Executive Director cum CEO to Managing Director cum CEO on the Board of Directors of the Company w.e.f. November 14, 2024 to hold Managing Director's office for a term upto 5 (Five) consecutive years from 14<sup>th</sup> November, 2024 to 13<sup>th</sup> November, 2029, subject to the ratification of the members in the ensuing General Meeting, and shall be liable to retire by rotation.







■ TEL. : 022 - 6825 2525  
■ FAX : 022 - 2405 7708  
■ E-Mail : info@naxparlab.com  
■ Visit us at: www.naxparlab.com  
■ CIN No. : L36912MH1982PLC027925

# Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,  
SION-CHUNABHATTI, MUMBAI - 400 022, INDIA

3. In supersession of the Ordinary Resolution, passed by the Members of the Company through Postal Ballot and Remote E-Voting on 05<sup>th</sup> July, 2024 for Appointment of Mr. Binoy Baiju Shah as the Managing Director and CFO of the Company, now the Nomination and Remuneration Committee (NRC) at its Meeting held prior to this Meeting has approved and recommended the Change in designation of Mr. Binoy Baiju Shah from Managing Director cum CFO to Executive Director cum CFO on the Board of Directors of the Company w.e.f. 14<sup>th</sup> November, 2024, subject to the ratification of the members in the ensuing General Meeting, and shall be liable to retire by rotation.

The details required along with brief profile under Regulation 30 of the Listing Regulations read with SEBI circular No. CIR/CFD/ CMD/4/2015 dated September 9, 2015 are given in the enclosed as Annexure I.

We, further affirm that Mr. Mihir Prakash Shah and Mr. Binoy Baiju Shah, have not been debarred from holding the office of the Director by virtue of any order of Securities and Exchange Board of India or such other authorities.

**The aforesaid information and Financial Results are being made available on the Company's website at [www.naxparlab.com](http://www.naxparlab.com)**

The meeting of the Board of Directors Commenced at 4.00 P.M. and Concluded at 04.45 P.M.

Kindly take on your record and acknowledge receipt of the same.

Thanking You,

Yours faithfully,

**For Parnax Lab Limited**

PREET  
VIJAY  
KUKREJA  
Digitally signed  
by PREET VIJAY  
KUKREJA  
Date: 2024.11.14  
16:13:46 +05'30'



**Preet Kukreja**  
**Company Secretary & Compliance Officer**  
**ACS No.: 56761**

Encl: As above





■ TEL : 022 - 6825 2525  
■ FAX : 022 - 2405 7708  
■ E-Mail : info@naxparlab.com  
■ Visit us at: www.naxparlab.com  
■ CIN No. : L36912MH1982PLC027925

# Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,  
SION-CHUNABHATTI, MUMBAI - 400 022. INDIA

## ANNEXURE I

### Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

| Sr. No. | Particulars  | Mr. Mihir P. Shah  | Mr. Binoy B. Shah   |
|---------|--|--|---|
| 1.      | Reason for change viz. <del>appointment, resignation, removal, death or otherwise</del>        | <b>Change of Designation</b>   | <b>Change of Designation</b>  |
| 2.      | Date of <del>appointment/</del> cessation (as applicable) & term of appointment/re-appointment | 14.11.2024<br><br>Change in designation of Mr. Mihir Prakash Shah from Executive Director cum CEO to Managing Director cum CEO on the Board of Directors of the Company w.e.f. November 14, 2024 to hold Managing Director's office for a term upto 5 (Five) consecutive years from 14 <sup>th</sup> November, 2024 to 13 <sup>th</sup> November, 2029, subject to the ratification of the members in the ensuing General Meeting, and shall be liable to retire by rotation.  | 14.11.2024<br><br>Change in designation of Mr. Binoy Baiju Shah from Managing Director cum CFO to Executive Director cum CFO on the Board of Directors of the Company w.e.f. 14 <sup>th</sup> November, 2024, subject to the ratification of the members in the ensuing General Meeting, and shall be liable to retire by rotation.         |
| 3.      | Brief profile (in case of Appointment)   | <p>Mr. Mihir Shah is having 30 years of Experience, and offering service in pharmaceutical and cosmetics manufacturing in Naxpar Group.</p> <p>Mr. Mihir P. Shah is committed to harnessing the growth potential of Naxpar Group by catering to the demands of the industry with professionalism and a differentiated service offering.</p> <p>At the core of Naxpar Group, Mr. Mihir Shah is one of the qualified and passionate in management team, who has behind him skill and experience. It is as a result of his diligence and perseverance that Naxpar's prowess in pharmaceutical manufacturing has seen exponential growth and achievement.</p> <p>He is Diligent in Strategy and planning, Deal Evaluation and Structuring.</p> | <p>Mr. Binoy Shah is having 19 years of Experience, and offering service in pharmaceutical and cosmetics manufacturing in Naxpar Group.</p> <p>Mr. Binoy B. Shah is committed to harnessing the growth potential of Naxpar Group by catering to the demands of the industry with professionalism and a differentiated service offering.</p> |







# Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,  
SION-CHUNABHATTI, MUMBAI - 400 022, INDIA

- TEL : 022 - 6825 2525
- FAX : 022 - 2405 7708
- E-Mail : info@naxparlab.com
- Visit us at: www.naxparlab.com
- CIN No. : L36912MH1982PLC027925

|    |  |    |  |  |
|----|--|----|--|--|
| 4. | Disclosure of relationships between directors (in case of appointment of a director) | of | Mr. Mihir Shah is related to following Directors of the Company: <ul style="list-style-type: none"><li>• Mrs. Ami Shah</li></ul> | Mr. Binoy Shah is related to following Directors of the Company: <ul style="list-style-type: none"><li>• Mrs. Ami Shah</li></ul> |
|----|--|----|--|--|

For Parnax Lab Limited

PREET  
VIJAY  
KUKREJA

Digitally signed  
by PREET VIJAY  
KUKREJA  
Date: 2024.11.14  
16:14:31 +05'30'



Preet Kukreja  
Company Secretary and Compliance Officer  
ACS No.: 56761



**C. N. PATEL & CO.**  
Chartered Accountants

Plot No. 12, Aradhana, State Bank Colony,  
Opp. Tidke Vidyalaya, Katol Road, Nagpur - 440013.  
Tel. No. +91 712 2584800, 9922584800  
Email ID : info@cnpca.in ☎ : www.cnpca.in

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM  
STANDALONE FINANCIAL RESULT**

**To The Board of Directors of Parnax Lab Limited,**

1. We have reviewed the unaudited standalone financial results of **Parnax Lab Limited** ("the Company") for the quarter and six month ended September 30, 2024 which are included in the accompanying "Statement of Unaudited Standalone Financial Results for the quarter and six month ended September 30, 2024" together with the relevant notes thereon ("the Statement"). The statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015") read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016.
2. The Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. The Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that cause us to believe that the accompanying Statement of unaudited standalone financial result has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For C N Patel & Co**  
**Chartered Accountants**  
**Firm Regd. No. 112552W**

*Manish*  
**CA Manish Mandhana**  
**Partner**  
**M. No. 112026**  
**UDIN :24112026BKFBSS6430**  
**Place: Mumbai**  
**Date: 14<sup>th</sup> November, 2024**





**PARNAX LAB LIMITED**

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022  
Tel: 022 - 6823 2525 Fax: 2405 7708, Email: info@maxparlab.com Website: www.maxparlab.com  
CIN: L36912MH1982PLC027925

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2024**

| S. No. | Particulars   | Quarter Ended             |                           |                           | Half Year Ended           |                           | Year Ended<br>31-03-2024<br>(Audited) |
|--------|---|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------------------|
|        |   | 30.09.2024<br>(Unaudited) | 30.06.2024<br>(Unaudited) | 30.09.2023<br>(Unaudited) | 30.09.2024<br>(Unaudited) | 30.09.2023<br>(Unaudited) |                                       |
| I      | Revenue from operations   | 153.58                    | 365.99                    | 183.21                    | 519.57                    | 296.44                    | 744.04                                |
| II     | Other income  | 18.07                     | 17.28                     | 18.10                     | 35.35                     | 29.58                     | 53.50                                 |
| III    | <b>Total Revenue (I+II)</b>   | <b>171.65</b>             | <b>383.27</b>             | <b>201.31</b>             | <b>554.92</b>             | <b>326.02</b>             | <b>797.54</b>                         |
| IV     | Expenses  |                           |                           |                           |                           |                           |                                       |
| a)     | Cost of material consumed   | 50.67                     | 22.09                     | 67.73                     | 72.76                     | 109.14                    | 231.53                                |
| b)     | Purchase of stock in trade  | 18.38                     | 111.04                    | 34.32                     | 129.42                    | 61.62                     | 68.34                                 |
| c)     | Changes in inventories of finished goods, Work in progress and stock in trade                               | -                         | -                         | (37.13)                   | -                         | (37.13)                   | -                                     |
| d)     | Employee benefit expenses   | 21.55                     | 20.99                     | 17.49                     | 42.54                     | 31.70                     | 73.64                                 |
| e)     | Finance costs   | 0.20                      | 0.72                      | 7.31                      | 0.92                      | 10.89                     | 14.10                                 |
| f)     | Depreciation and amortisation expenses  | 1.60                      | 1.58                      | 1.82                      | 3.18                      | 2.90                      | 5.83                                  |
| g)     | Other expenses  | 43.11                     | 86.55                     | 30.75                     | 129.66                    | 58.94                     | 159.41                                |
|        | <b>Total Expenses (IV)</b>  | <b>135.51</b>             | <b>242.97</b>             | <b>122.29</b>             | <b>378.48</b>             | <b>238.06</b>             | <b>552.85</b>                         |
| V      | <b>Profit/(loss) before exceptional items and tax (III-IV)</b>  | <b>36.14</b>              | <b>140.30</b>             | <b>79.02</b>              | <b>176.44</b>             | <b>87.96</b>              | <b>244.69</b>                         |
| VI     | Exceptional items   | -                         | -                         | -                         | -                         | -                         | -                                     |
| VII    | <b>Profit/(loss) before tax (V-VI)</b>  | <b>36.14</b>              | <b>140.30</b>             | <b>79.02</b>              | <b>176.44</b>             | <b>87.96</b>              | <b>244.69</b>                         |
| VIII   | Tax expense   | -                         | -                         | -                         | -                         | -                         | -                                     |
| a)     | Current tax   | -                         | -                         | -                         | -                         | -                         | -                                     |
| b)     | Deferred tax  | 9.09                      | 35.31                     | 19.34                     | 44.40                     | 21.63                     | 62.34                                 |
| c)     | Short (Excess) provision for tax for earlier years  | -                         | -                         | -                         | -                         | -                         | -                                     |
| IX     | <b>Profit (loss) for the period (VII-VIII)</b>  | <b>27.05</b>              | <b>104.99</b>             | <b>59.68</b>              | <b>132.04</b>             | <b>66.33</b>              | <b>182.35</b>                         |
| X      | Other comprehensive income  |                           |                           |                           |                           |                           |                                       |
| A.     | (i) Items that will not be reclassified to profit or loss   | -                         | -                         | -                         | -                         | -                         | (3.23)                                |
|        | (ii) Income tax relating to items that will not be reclassified to profit or loss                           | -                         | -                         | -                         | -                         | -                         | 0.81                                  |
| B.     | (i) Items that will be reclassified to profit or loss   | -                         | -                         | -                         | -                         | -                         | -                                     |
|        | (ii) Income tax relating to items that will be reclassified to profit or loss                               | -                         | -                         | -                         | -                         | -                         | -                                     |
| XI     | <b>Total other comprehensive income for the period</b>  | <b>-</b>                  | <b>-</b>                  | <b>-</b>                  | <b>-</b>                  | <b>-</b>                  | <b>(2.42)</b>                         |
|        | <b>Total Comprehensive Income comprising profit and other comprehensive income for the period (VIII+IX)</b> | <b>27.05</b>              | <b>104.99</b>             | <b>59.68</b>              | <b>132.04</b>             | <b>66.33</b>              | <b>179.93</b>                         |
| XII    | <b>Paid-up equity share capital (Face Value of the share Rs. 10)</b>  | <b>1,148.56</b>           | <b>1,148.56</b>           | <b>1,148.56</b>           | <b>1,148.56</b>           | <b>1,148.56</b>           | <b>1,148.56</b>                       |
| XIII   | <b>Earning per equity share (Not annualised)</b>  |                           |                           |                           |                           |                           |                                       |
| (1)    | Basic   | 0.24                      | 0.91                      | 0.52                      | 1.15                      | 0.58                      | 1.59                                  |
| (2)    | Diluted   | 0.24                      | 0.91                      | 0.52                      | 1.15                      | 0.58                      | 1.59                                  |

**Notes-**

- The Financial results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 14, 2024.
- The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter and half year ended September 30, 2024.
- EPS for quarter ended is on non annualised basis.
- The Company is dealing into one segment: Dealing in Pharmaceutical Formulations
- Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.



By Order of the Board  
For Parnax Lab Limited

*B. B. Shah*

Binoy B. Shah  
Director & CFO  
JIN NO: 00440880

Place: Mumbai  
Date: 14-11-2024



# PARNAX LAB LIMITED

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.

Tel : 022 - 6825 2525, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com

CIN:-L36912MH1982PLC027925

## Statement of Standalone Assets and Liabilities as at 30th September, 2024

(Rs. in Lakhs)

| S. No.   | Particulars                         | Standalone                |                           |                         |
|--|-------------------------------------|---------------------------|---------------------------|-------------------------|
|  |                                     | 30.09.2024<br>(Unaudited) | 30.09.2023<br>(Unaudited) | 31.03.2024<br>(Audited) |
| <b>A</b>   | <b>ASSETS</b>                       |                           |                           |                         |
| <b>1</b>   | <b>Non-Current Assets</b>           |                           |                           |                         |
| (a)  | Property, plant and equipment       | 45.60                     | 51.54                     | 48.77                   |
| (b)  | Capital work-in-progress            | -                         | -                         | -                       |
| (c)  | Investment Property                 | -                         | -                         | -                       |
| (d)  | Other Intangible assets             | 0.07                      | 0.09                      | 0.08                    |
| (e)  | <b>Financial assets</b>             |                           |                           |                         |
| (i)  | Investments                         | 1,003.08                  | 1,003.08                  | 1,003.08                |
| (ii)   | Other non-current financial assets  | 0.25                      | 0.25                      | 0.25                    |
| (f)  | Deferred tax assets (net)           | -                         | 45.40                     | 5.51                    |
| <b>2</b>   | <b>Current Assets</b>               |                           |                           |                         |
| (a)  | Inventories                         | 29.50                     | 71.49                     | 90.11                   |
| (b)  | <b>Financial assets</b>             |                           |                           |                         |
| (i)  | Investments                         | -                         | -                         | -                       |
| (ii)   | Trade Receivables                   | 162.87                    | 59.79                     | 59.44                   |
| (iii)  | Cash and cash equivalents           | 16.07                     | 87.25                     | 43.97                   |
| (iv)   | Bank balances other than above      | 1.70                      | 1.55                      | 1.70                    |
| (v)  | Loans                               | 701.35                    | 413.20                    | 527.11                  |
| (c)  | Current tax assets (Net)            | 3.09                      | 1.67                      | 3.09                    |
| (d)  | Other current assets                | 46.31                     | 52.06                     | 78.42                   |
| (e)  | Assets classified as held for sale  | 357.61                    | 372.00                    | 362.12                  |
|  | <b>TOTAL - ASSETS</b>               | <b>2,367.50</b>           | <b>2,159.37</b>           | <b>2,223.65</b>         |
| <b>B</b>   | <b>EQUITY AND LIABILITIES</b>       |                           |                           |                         |
| <b>1</b>   | <b>Equity</b>                       |                           |                           |                         |
| (a)  | Equity share capital                | 1,148.56                  | 1,148.56                  | 1,148.56                |
| (b)  | Other equity                        | 1,098.82                  | 853.18                    | 966.78                  |
| <b>2</b>   | <b>Liabilities</b>                  |                           |                           |                         |
| <b>(I)</b>   | <b>Non-current liabilities</b>      |                           |                           |                         |
| (a)  | Financial liabilities               |                           |                           |                         |
| (i)  | Borrowings                          | -                         | -                         | -                       |
| (b)  | Provisions                          | 2.28                      | 0.95                      | 2.28                    |
| (c)  | Deferred tax liabilities (Net)      | 38.89                     | -                         | -                       |
| (d)  | Other non - current liabilities     | -                         | -                         | -                       |
| <b>(II)</b>  | <b>Current liabilities</b>          |                           |                           |                         |
| (a)  | Financial liabilities               |                           |                           |                         |
| (i)  | Borrowings                          | -                         | 63.07                     | -                       |
| (ii)   | Trade payables                      |                           |                           |                         |
| - total outstanding dues of micro enterprises and small enterprises                    |                                     | -                         | 33.65                     | 5.09                    |
| - total outstanding dues of creditors other than micro enterprise and small enterprise |                                     | 9.54                      | 18.96                     | 65.67                   |
| (iii)  | Other current financial liabilities | 50.40                     | 34.64                     | 26.40                   |
| (b)  | Other current liabilities           | 18.25                     | 6.16                      | 8.11                    |
| (c)  | Short-term provisions               | 0.76                      | 0.20                      | 0.76                    |
|  | <b>TOTAL EQUITY AND LIABILITIES</b> | <b>2,367.50</b>           | <b>2,159.37</b>           | <b>2,223.65</b>         |



By Order of the Board  
For Parnax Lab Limited

*B. B. Shah*

Binoy B. Shah

Director & CFO

DIN NO: 00440880

Place : Mumbai

Date : 14-11-2024



**PARNAX LAB LIMITED**

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.

Tel : 022 - 6825 2525, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com

CIN:-L36912MH1982PLC027925

**Standalone Cash Flow Statement for the period ended 30th September, 2024**

(Rs. in Lakhs)

| Particulars  | For the period ended 30th September, 2024 | For the period ended 30th September, 2023 | For the year ended 31st March 2024 |
|--|---|---|------------------------------------|
|  | (Unaudited)                               | (Unaudited)                               | (Audited)                          |
| <b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>                          |   |   |                                    |
| Net Profit/(Loss) before tax   | 176.44                                    | 87.96                                     | 244.69                             |
| <b>Adjustments for</b>   |   |   |                                    |
| Depreciation   | 3.18                                      | 2.90                                      | 5.83                               |
| Finance Costs  | 0.92                                      | 10.89                                     | 14.10                              |
| Loss on sale of Property, plant & equipments                           | -   | -   | -                                  |
| Sundry Balances written off  | -   | 0.02                                      | -                                  |
| Interest & Dividend income   | (22.73)                                   | (14.84)                                   | (30.49)                            |
| <b>Operating Loss Before Working Capital Adjustments</b>               | <b>157.81</b>                             | <b>86.93</b>                              | <b>234.13</b>                      |
| <b>Changes in Working Capital</b>                                      |   |   |                                    |
| <u>Adjustments for (increase) / decrease in operating assets:</u>      |   |   |                                    |
| Inventories  | 60.62                                     | (13.92)                                   | (32.55)                            |
| Trade receivables  | (103.44)                                  | 48.18                                     | 48.54                              |
| Other assets (Financials and Non Financial assets)                     | (142.13)                                  | (111.04)                                  | (251.31)                           |
| <u>Adjustments for increase / (decrease) in operating liabilities:</u> |   |   |                                    |
| Trade payables   | (61.22)                                   | 9.25                                      | 27.42                              |
| Other liabilities (Financials and Non Financial assets)                | 34.14                                     | (8.75)                                    | (16.38)                            |
| <b>Cash generated from operations</b>                                  | <b>(54.22)</b>                            | <b>10.65</b>                              | <b>9.85</b>                        |
| Direct Tax Paid (Refund) [Net]   | -   | 0.06                                      | 1.49                               |
| <b>Net cash flow from / (used in) operating activities (A)</b>         | <b>(54.22)</b>                            | <b>10.59</b>                              | <b>8.36</b>                        |
| <b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>                          |   |   |                                    |
| Expenditure on asset held for disposal                                 | -   | -   | (7.95)                             |
| Purchase of property, plant & equipment                                | -   | (19.86)                                   | (12.06)                            |
| Proceeds from sale of fixed assets                                     | 4.51                                      | 10.00                                     | 19.88                              |
| Purchase of Non Current Investments                                    | -   | -   | (0.15)                             |
| Proceeds/(Purchase) from sale of Non Current Investments               | -   | -   | -                                  |
| Interest & Dividend income   | 22.73                                     | 14.84                                     | 30.49                              |
| <b>Net cash flow from / (used in) investing activities (B)</b>         | <b>27.24</b>                              | <b>4.98</b>                               | <b>30.21</b>                       |
| <b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>                          |   |   |                                    |
| Proceeds from Issue of Shares, Warrants                                | -   | -   | -                                  |
| Repayment of long-term borrowings                                      | -   | -   | -                                  |
| Net increase / (decrease) in working capital borrowings                | -   | -   | -                                  |
| Proceeds from long-term borrowings (net)                               | -   | (16.08)                                   | (16.08)                            |
| Proceeds from Short-term borrowings (net)                              | -   | (27.99)                                   | (91.06)                            |
| Finance Cost   | (0.92)                                    | (10.89)                                   | (14.10)                            |
| <b>Net cash flow from / (used in) financing activities (C)</b>         | <b>(0.92)</b>                             | <b>(54.96)</b>                            | <b>(121.24)</b>                    |
| <b>Net increase (decrease) in cash and cash equivalents (A+B+C)</b>    | <b>(27.90)</b>                            | <b>(39.39)</b>                            | <b>(82.67)</b>                     |
| <b>Cash and cash equivalents at the beginning of the year</b>          | <b>43.97</b>                              | <b>126.64</b>                             | <b>126.64</b>                      |
| <b>Cash and cash equivalents at the end of the year</b>                | <b>16.07</b>                              | <b>87.25</b>                              | <b>43.97</b>                       |

By Order of the Board  
For Parnax Lab Limited



*B. B. Shah*

Binoy B. Shah  
Director & CFO  
DIN NO: 00440880

Place : Mumbai  
Date : 14-11-2024





**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM  
CONSOLIDATED FINANCIAL RESULT**

**TO THE BOARD OF DIRECTORS OF**

**Parnax Lab Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Parnax Lab Limited** ("the Parent") and its subsidiary Naxpar Pharma Private Limited (the Parent and its subsidiary together referred to as "the Group") for the quarter and six month ended September 30, 2024, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

**Naxpar Pharma Private Limited - Subsidiary**

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.






6. We did not review the interim financial statements of Naxpar Pharma Private Limited, subsidiary respectively included in the consolidated unaudited financial results, whose interim financial statements reflect total assets of Rs. 17,359.95 lakhs as at September 30, 2024 and total revenues of Rs. 9,502.39 lakhs, total net profit after tax of Rs. 608.09 lakhs and total comprehensive income of Rs. 608.09, for the quarter and six month ended September 30, 2024 respectively, as considered in the consolidated unaudited financial results. These interim financial statements have been reviewed by the other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiary, is based solely on the reports of the other auditors and the procedure performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

**For C N Patel & Co**  
**Chartered Accountants**  
**Firm Regd. No. 112552W**

  
**CA Manish Mandhana**  
**Partner**  
**M. No. 112026**  
**UDIN :24112026BKFBST8385**



**Place: Mumbai**  
**Date: 14<sup>th</sup> November, 2024**



**PARNAX LAB LIMITED**

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.  
Tel : 022 - 6825 2525, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com  
CIN:-L36912MH1982PLC027925

**STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEARENDED 30.09.2024**

| S. No. | Particulars   | Quarter Ended             |                           |                           |                           | Half Year Ended           |                  | (Rs. in Lakhs)<br>Year Ended<br>31.03.2024<br>(Audited) |
|--------|---|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|------------------|---|
|        |   | 30.09.2024<br>(Unaudited) | 30.06.2024<br>(Unaudited) | 30.09.2023<br>(Unaudited) | 30.09.2024<br>(Unaudited) | 30.09.2023<br>(Unaudited) |                  |   |
|        |   |                           |                           |                           |                           |                           |                  |   |
| I      | Revenue from operations   | 4,836.29                  | 5,012.03                  | 4,261.15                  | 9,848.32                  | 9,135.33                  | 18,871.12        |   |
| II     | Other income  | 94.95                     | 11.18                     | 22.30                     | 106.13                    | 46.74                     | 81.57            |   |
| III    | <b>Total Revenue (I+II)</b>   | <b>4,931.24</b>           | <b>5,023.21</b>           | <b>4,283.45</b>           | <b>9,954.45</b>           | <b>9,182.07</b>           | <b>18,952.69</b> |   |
| IV     | <b>Expenses</b>   |                           |                           |                           |                           |                           |                  |   |
|        | a) Cost of material consumed  | 2,151.92                  | 2,330.56                  | 2,292.07                  | 4,482.48                  | 4,984.95                  | 10,473.53        |   |
|        | b) Purchase of stock in trade   | 13.61                     | 36.83                     | 41.11                     | 50.44                     | 68.97                     | 15.02            |   |
|        | c) Changes in inventories of finished goods, Work in progress and stock in trade                            | 300.00                    | (17.29)                   | (170.89)                  | 282.71                    | (138.05)                  | (207.11)         |   |
|        | d) Employee benefit expenses  | 612.17                    | 642.04                    | 576.42                    | 1,254.21                  | 1,144.55                  | 2,372.17         |   |
|        | e) Finance costs  | 138.46                    | 149.75                    | 142.97                    | 288.21                    | 258.68                    | 534.58           |   |
|        | f) Depreciation and amortisation expenses   | 193.60                    | 182.92                    | 173.84                    | 376.52                    | 334.02                    | 696.44           |   |
|        | g) Other expenses   | 1,034.25                  | 1,158.21                  | 993.88                    | 2,192.46                  | 1,896.83                  | 3,863.09         |   |
|        | h) Impairment of assets classified as held for disposal   |                           |                           |                           |                           |                           |                  |   |
| V      | <b>Total Expenses (IV)</b>  | <b>4,444.01</b>           | <b>4,483.02</b>           | <b>4,049.40</b>           | <b>8,927.03</b>           | <b>8,549.95</b>           | <b>17,747.72</b> |   |
| VI     | <b>Profit/(loss) before exceptional items and tax (III-IV)</b>  | <b>487.23</b>             | <b>540.19</b>             | <b>234.05</b>             | <b>1,027.42</b>           | <b>632.12</b>             | <b>1,204.97</b>  |   |
| VII    | <b>Profit/(loss) Before Tax (V-VI)</b>  | <b>487.23</b>             | <b>540.19</b>             | <b>234.05</b>             | <b>1,027.42</b>           | <b>632.12</b>             | <b>1,204.97</b>  |   |
| VIII   | <b>Tax expense</b>  |                           |                           |                           |                           |                           |                  |   |
|        | a) Current Tax  | 119.40                    | 91.60                     | 17.00                     | 211.00                    | 105.00                    | 193.28           |   |
|        | b) Deferred Tax   | 26.39                     | 49.91                     | 29.87                     | 76.30                     | 7.06                      | 82.25            |   |
|        | c) Short (Excess) Prov for Tax for Earlier Years  | -                         | -                         | -                         | -                         | -                         | (33.04)          |   |
| IX     | <b>Profit/(Loss) for the period (VII-VIII)</b>  | <b>341.44</b>             | <b>398.68</b>             | <b>187.18</b>             | <b>740.12</b>             | <b>520.06</b>             | <b>962.48</b>    |   |
| X      | Minority Interest Profit (Loss)   | 0.63                      | 0.59                      | 0.26                      | 1.22                      | 0.91                      | 1.56             |   |
| XI     | <b>Profit/ (Loss) after share of Profit (Loss) of Minority Interest</b>                                     | <b>340.81</b>             | <b>398.09</b>             | <b>186.92</b>             | <b>738.90</b>             | <b>519.15</b>             | <b>960.92</b>    |   |
| XII    | <b>Other Comprehensive Income</b>   |                           |                           |                           |                           |                           |                  |   |
|        | A. (i) Items that will not be reclassified to profit or loss  | -                         | -                         | -                         | -                         | -                         | (25.52)          |   |
|        | (ii) Income tax relating to items that will not be reclassified to profit or loss                           | -                         | -                         | -                         | -                         | -                         | 6.42             |   |
|        | B. (i) Items that will be reclassified to profit or loss  | -                         | -                         | -                         | -                         | -                         | -                |   |
|        | (ii) Income tax relating to items that will be reclassified to profit or loss                               | -                         | -                         | -                         | -                         | -                         | -                |   |
| XIII   | <b>Total Other Comprehensive Income for the period</b>  | <b>-</b>                  | <b>-</b>                  | <b>-</b>                  | <b>-</b>                  | <b>-</b>                  | <b>(19.10)</b>   |   |
| XIV    | <b>Total Comprehensive Income comprising profit and other comprehensive income for the period (VIII+IX)</b> | <b>341.44</b>             | <b>398.68</b>             | <b>187.18</b>             | <b>740.12</b>             | <b>520.06</b>             | <b>943.38</b>    |   |





| S. No. | Particulars  | Quarter Ended             |                           | Half Year Ended           |                           | Year Ended<br>31.03.2024<br>(Audited) |
|--------|--|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------------------|
|        |  | 30.09.2024<br>(Unaudited) | 30.06.2024<br>(Unaudited) | 30.09.2023<br>(Unaudited) | 30.09.2024<br>(Unaudited) |                                       |
| XV     | <b>Total profit/(loss) for the year attributable to:</b>             |                           |                           |                           |                           |                                       |
|        | - Owners of the Company  | 340.81                    | 398.09                    | 186.92                    | 738.90                    | 960.92                                |
|        | - Non-controlling interests  | 0.63                      | 0.59                      | 0.26                      | 1.22                      | 1.56                                  |
| XVI    | <b>Other Comprehensive income attributable to :</b>                  |                           |                           |                           |                           |                                       |
|        | - Owners of the Company  |                           | -                         |                           | -                         | (19.07)                               |
|        | - Non-controlling interests  |                           | -                         |                           | -                         | (0.03)                                |
| XVII   | <b>Total Comprehensive income attributable to:</b>                   |                           |                           |                           |                           |                                       |
|        | - Owners of the Company  | 340.81                    | 398.09                    | 186.92                    | 738.90                    | 941.85                                |
|        | - Non-controlling interests  | 0.63                      | 0.59                      | 0.26                      | 1.22                      | 1.53                                  |
| XVIII  | <b>Paid-up equity share capital (Face Value of the share Rs. 10)</b> | 1,148.56                  | 1,148.96                  | 1,148.56                  | 1,148.56                  | 1,148.56                              |
| XIX    | <b>Earning per equity share (Not Annualised)</b>                     |                           |                           |                           |                           |                                       |
|        | (1) Basic  | 2.97                      | 3.47                      | 1.63                      | 6.44                      | 8.38                                  |
|        | (2) Diluted  | 2.97                      | 3.47                      | 1.63                      | 6.44                      | 8.38                                  |

**Notes-**

- The Financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended) and SEBI circular dated 5th July, 2016.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 14, 2024.
- The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter and half year ended September 30, 2024.
- EPS for quarter ended is on non annualised basis.
- The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
- Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

By Order of the Board  
For Parnax Lab Limited



*Brijesh*

Binoy B. Shah  
Director & CFO  
DIN: 00440880

Place : Mumbai  
Date : 14-11-2024



**PARNAX LAB LIMITED**

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.

Tel : 022 - 6825 2525, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com

CIN:-L36912MH1982PLC027925

**Statement of Consolidated Assets and Liabilities as at 30th September, 2024**

(Rs. in Lakhs)

| S. No.      | Particulars  | Consolidated              |                           |                         |
|-------------|--|---------------------------|---------------------------|-------------------------|
|             |  | 30.09.2024<br>(Unaudited) | 30.09.2023<br>(Unaudited) | 31.03.2024<br>(Audited) |
| <b>A</b>    | <b>ASSETS</b>  |                           |                           |                         |
| <b>1</b>    | <b>Non-Current Assets</b>  |                           |                           |                         |
| (a)         | Property, plant and equipment  | 8,113.95                  | 7,918.13                  | 7,938.56                |
| (b)         | Right-of-use asset   | 2,364.07                  | 908.89                    | 2,060.98                |
| (c)         | Capital work-in-progress   | 75.69                     | 73.69                     | 78.96                   |
| (d)         | Other Intangible assets  | 877.74                    | 19.70                     | 930.80                  |
| (e)         | <b>Financial assets</b>  |                           |                           |                         |
| (i)         | Investments  | 16.08                     | 16.08                     | 16.08                   |
| (ii)        | Other non-current financial assets   | 74.20                     | 91.91                     | 67.83                   |
| (f)         | Deferred tax assets (net)  |                           |                           |                         |
| (g)         | Other non-current assets   | 315.83                    | 179.73                    | 240.12                  |
| <b>2</b>    | <b>Current Assets</b>  |                           |                           |                         |
| (a)         | Inventories  | 2,163.42                  | 2,608.94                  | 2,992.76                |
| (b)         | <b>Financial assets</b>  |                           |                           |                         |
| (i)         | Trade Receivables  | 3,034.56                  | 2,910.36                  | 3,255.94                |
| (ii)        | Cash and cash equivalents  | 17.67                     | 89.19                     | 45.78                   |
| (iii)       | Bank balances other than above   | 149.93                    | 134.87                    | 141.93                  |
| (iv)        | Loans  | 17.99                     | 21.01                     | 23.48                   |
| (c)         | Current tax assets (Net)   | 19.66                     | 18.24                     | 87.27                   |
| (d)         | Other current assets   | 427.29                    | 410.67                    | 633.98                  |
| (e)         | Assets classified as held for sale   | 357.60                    | 372.00                    | 362.12                  |
|             | <b>TOTAL - ASSETS</b>  | <b>18,025.68</b>          | <b>15,773.41</b>          | <b>18,876.59</b>        |
| <b>B</b>    | <b>EQUITY AND LIABILITIES</b>  |                           |                           |                         |
| <b>1</b>    | <b>Equity</b>  |                           |                           |                         |
| (a)         | Equity share capital   | 1,148.56                  | 1,148.56                  | 1,148.56                |
| (b)         | Other equity   | 6,747.61                  | 5,586.00                  | 6,008.70                |
|             | <b>Equity attributable to owner</b>  | <b>7,896.17</b>           | <b>6,734.56</b>           | <b>7,157.26</b>         |
|             | Non Controlling Interest   | 13.41                     | 11.58                     | 12.19                   |
|             | <b>Total Equity</b>  | <b>7,909.58</b>           | <b>6,746.14</b>           | <b>7,169.45</b>         |
| <b>2</b>    | <b>Liabilities</b>   |                           |                           |                         |
| <b>(I)</b>  | <b>Non-current liabilities</b>   |                           |                           |                         |
| (a)         | <b>Financial liabilities</b>   |                           |                           |                         |
| (i)         | Borrowings   | 1,899.01                  | 1,101.69                  | 2,105.31                |
| (ii)        | Lease Liabilities  | 854.56                    | 876.89                    | 888.92                  |
| (b)         | Provisions   | 30.88                     | 20.79                     | 61.20                   |
| (c)         | Deferred tax liabilities (Net)   | 544.90                    | 399.83                    | 468.60                  |
| <b>(II)</b> | <b>Current liabilities</b>   |                           |                           |                         |
| (a)         | <b>Financial liabilities</b>   |                           |                           |                         |
| (i)         | Borrowings   | 4,700.58                  | 3,885.32                  | 5,000.98                |
| (ii)        | Trade payables   |                           |                           |                         |
|             | - total outstanding dues of micro enterprises and enterprises                    | 102.94                    | 417.71                    | 298.64                  |
|             | - total outstanding dues of creditors other than enterprise and small enterprise | 789.80                    | 1,340.58                  | 1919.73                 |
| (iii)       | Lease Liabilities  | 69.51                     | 39.38                     | 68.67                   |
| (iv)        | Other current financial liabilities  | 801.12                    | 831.91                    | 819.67                  |
| (b)         | Other current liabilities  | 308.56                    | 55.62                     | 68.00                   |
| (c)         | Short-term provisions  | 7.42                      | 23.20                     | 7.42                    |
| (d)         | Current Tax Liability (net)  | 6.82                      | 34.35                     | -                       |
|             | <b>Total Liability</b>   | <b>10,116.10</b>          | <b>9,027.27</b>           | <b>11,707.14</b>        |
|             | <b>TOTAL EQUITY AND LIABILITIES</b>  | <b>18,025.68</b>          | <b>15,773.41</b>          | <b>18,876.59</b>        |



By Order of the Board  
For Parnax Lab Limited

*B. B. Shah*

Binoy B. Shah

Director & CFO

DIN NO: 00440880

Place : Mumbai  
Date : 14-11-2024



**PARNAX LAB LIMITED**

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.

Tel : 022 - 6825 2525, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com

CIN:-L36912MH1982PLC027925

**Consolidated Cash Flow Statement for the period ended 30th September, 2024**

(Rs. in Lakhs)

| Particulars  | For the period ended 30th September, 2024 (Unaudited) | For the period ended 30th September, 2023 (Unaudited) | For the year ended 31st March 2024 (Audited) |
|--|---|---|--|
| <b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>                          |   |   |  |
| Net Profit/(Loss) before tax   | 1,027.42  | 632.12  | 1,204.97                                     |
| <b>Adjustments for</b>   |   |   |  |
| Depreciation   | 376.53  | 334.02  | 696.44                                       |
| Finance Cost   | 288.21  | 258.68  | 534.58                                       |
| Loss/(Profit) on sale of Property, plant & equipments                  |   | (0.78)  | -  |
| Lease Modification   | 2.28  | (3.13)  |  |
| Sundry Balances written off  |   | (0.06)  | (3.19)                                       |
| Interest & Dividend income   | (9.31)  | (2.09)  | (41.51)                                      |
| <b>Operating Loss Before Working Capital Adjustments</b>               | <b>1,685.13</b>                                       | <b>1,218.77</b>                                       | <b>2,391.29</b>                              |
| <b>Changes in Working Capital</b>                                      |   |   |  |
| <u>Adjustments for (increase) / decrease in operating assets:</u>      |   |   |  |
| Inventories  | 829.34  | (440.25)  | (824.07)                                     |
| Trade receivables  | 221.38  | (121.10)  | (466.68)                                     |
| Other assets (Financials and Non Financial assets)                     | 130.12  | 115.82  | (16.09)                                      |
| <u>Adjustments for increase / (decrease) in operating liabilities:</u> |   |   |  |
| Trade payables   | (1,325.64)  | 281.92  | 742.02                                       |
| Other liabilities (Financials and Non Financial assets)                | 191.70  | 26.00   | 25.24  |
| <b>Cash generated from operations</b>                                  | <b>1,732.03</b>                                       | <b>1,081.16</b>                                       | <b>1,851.71</b>                              |
| Direct Tax Paid (Refund) [Net]   | 136.57  | 105.47  | 264.00                                       |
| <b>Net cash flow from / (used in) operating activities (A)</b>         | <b>1,595.46</b>                                       | <b>975.69</b>   | <b>1,587.71</b>                              |
| <b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>                          |   |   |  |
| Purchase of property, plant & equipment                                | (574.74)  | (983.27)  | (1,413.51)                                   |
| Expenditure on capital work in progress                                | (303.09)  | 159.29  | (1,827.99)                                   |
| Expenditure on asset held for disposal                                 |   | -   | (7.95)                                       |
| Investment in fixed deposit  | (8.00)  | 15.28   | 8.22   |
| Proceeds from sale of fixed assets                                     | 47.86   | 34.00   | 48.13  |
| Proceeds (Purchase) from sale of Non Current Investments               |   | -   | -  |
| Interest & Dividend income   | 9.31  | 2.09  | 41.51  |
| <b>Net cash flow from / (used in) investing activities (B)</b>         | <b>(828.66)</b>                                       | <b>(772.61)</b>                                       | <b>(3,151.59)</b>                            |
| <b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>                          |   |   |  |
| Proceeds from Issue of Shares, Warrants                                | -   | -   | -  |
| Proceeds from long-term, borrowings (net)                              | (206.30)  | (100.69)  | 902.93                                       |
| Proceeds from short-term, borrowings (net)                             | (300.40)  | 117.54  | 1,113.36                                     |
| Finance Cost   | (288.21)  | (258.68)  | (534.58)                                     |
| <b>Net cash flow from / (used in) financing activities (C)</b>         | <b>(794.91)</b>                                       | <b>(241.84)</b>                                       | <b>1,481.71</b>                              |
| <b>Net increase (decrease) in cash and cash equivalents (A+B+C)</b>    | <b>(28.11)</b>  | <b>(38.76)</b>  | <b>(82.17)</b>                               |
| <b>Cash and cash equivalents at the beginning of the year</b>          | <b>45.78</b>  | <b>127.95</b>   | <b>127.95</b>                                |
| <b>Cash and cash equivalents at the end of the year</b>                | <b>17.67</b>  | <b>89.19</b>  | <b>45.78</b>                                 |



By Order of the Board  
For Parnax Lab Limited

*B. B. Shah*

Binoy B. Shah  
Director & CFO  
DIN NO: 00440880

Place : Mumbai  
Date : 14-11-2024